GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » General Biologicals Corp (ROCO:4117) » Definitions » EBIT

General Biologicals (ROCO:4117) EBIT : NT$-189.2 Mil (TTM As of Jun. 2024)


View and export this data going back to 2002. Start your Free Trial

What is General Biologicals EBIT?

General Biologicals's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was NT$-99.4 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-189.2 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. General Biologicals's annualized ROC % for the quarter that ended in Jun. 2024 was -7.20%. General Biologicals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -8.61%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. General Biologicals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -7.07%.


General Biologicals EBIT Historical Data

The historical data trend for General Biologicals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

General Biologicals EBIT Chart

General Biologicals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -34.37 51.61 49.61 -29.27 -175.74

General Biologicals Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.80 -58.07 -85.93 -89.81 -99.38

Competitive Comparison of General Biologicals's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, General Biologicals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


General Biologicals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, General Biologicals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where General Biologicals's EV-to-EBIT falls into.


;
;

General Biologicals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-189.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


General Biologicals  (ROCO:4117) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

General Biologicals's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-191.576 * ( 1 - 0.14% )/( (2326.641 + 2988.605)/ 2 )
=-191.3077936/2657.623
=-7.20 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2537.333 - 838.137 - ( 217.123 - max(0, 1029.297 - 401.852+217.123))
=2326.641

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3159.951 - 162.254 - ( 216.665 - max(0, 407.523 - 416.615+216.665))
=2988.605

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

General Biologicals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-198.75/( ( (2002.499 + max(-725.477, 0)) + (2612.923 + max(-12.821, 0)) )/ 2 )
=-198.75/( ( 2002.499 + 2612.923 )/ 2 )
=-198.75/2307.711
=-8.61 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(33.801 + 85.556 + 14.088) - (838.137 + 0 + 20.785)
=-725.477

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(55.107 + 106.532 + 27.165) - (162.254 + 0 + 39.371)
=-12.821

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

General Biologicals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=-189.18/2675.041
=-7.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


General Biologicals EBIT Related Terms

Thank you for viewing the detailed overview of General Biologicals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


General Biologicals Business Description

Traded in Other Exchanges
N/A
Address
No-6, Innovation First Road, Hsinchu Science Park, Hsinchu, TWN, 300092
General Biologicals Corp is a developer and manufacturer of vitro diagnostic devices in Taiwan. It offers research development, marketing and servicing of products and solutions for hospitals, medical laboratories, blood banks, and research and industry. Its products include Anti-HDV, HIV Ag-Ab COMB, Anti-HBs, and many others.

General Biologicals Headlines

No Headlines